Arisan Therapeutics

Executive Summary

Arisan Therapeutics is a private biotechnology company founded in 2020 and headquartered in Carlsbad, California. The company is dedicated to discovering and developing novel small-molecule antiviral therapeutics for neglected and emerging infectious diseases, with an initial focus on COVID-19 and influenza. Despite being founded over five years ago, Arisan remains in the early preclinical stage with no disclosed funding rounds, clinical pipelines, or partnerships. The company's website and public information are minimal, suggesting it operates under the radar. The antiviral space is competitive, but Arisan's niche focus on neglected diseases could provide differentiation if it can advance candidates into clinical development. However, the lack of transparency on its programs and financial status makes it difficult to assess its progress or near-term potential. The company has not reported any significant milestones, such as IND filings or licensing deals, and its profile scores are low, indicating limited market visibility and engagement.

Upcoming Catalysts (preview)

• 2026Series A funding announcement40% success
• 2027Preclinical proof-of-concept data for lead antiviral candidate30% success
• TBDPartnership or licensing deal for COVID-19 or influenza program25% success